

# Challenges with sedation of patients with COVID-19 in the ICU

Alice Gallo de Moraes, MD, FACP @gallodemoraesMD

ATS COVID-19 Critical Care Training Forum

@gallodemoraesMD

©2016 MFMER | slide-1

## Disclosures

None



@gallodemoraesMD

02016 MFMER | slide-2

### Learning Objectives

- Select the best sedative agent for each individual patient/situation
- Identify "unpopular" drugs that can be helpful during COVID (and probably not forgotten ever again)
- Identify the medications at highest risk of shortage
- Identifying post-extubation challenges



#### Agent selection

- Etiology of respiratory distress
  - Association of pain, anxiety and delirium
- Expected duration of mechanical ventilation
  - Shorter propofol
  - Longer benzos
- Nonpharmacological strategies
- COVID: patients requiring MV for longer than expected; inability to provide some of the proven nonpharmacological therapies



### Remember the "unpopular" drugs

- Ketamine
  - Potent sedative with marked analgesia
  - Minimal hemodynamic effect
  - Dissociative experiences prevented with benzos
- Haldol
  - Moderate sedation through dopamine2 antagonism
  - Boluses versus drip



#### Remember the "unpopular" drugs

- NSAIDS
  - Remember agitation and delirium can be due to pain
  - No solid evidence that they must be avoided in COVID
- Phenobarbital
  - May cause bradycardia and hypotension
  - Half life is about 70 hours



#### **Medication Shortage**

- Likely unique to each hospital/regional practices
- Communicate with the pharmacists at your hospital frequently.



@gallodemoraesMD

©2016 MFMER | slide-7

#### **Post-extubation challenges**

- Weakness
  - Secondary to prolonged intubation/paralysis
- Nutrition
  - Dysphagia
  - Elevation of triglycerides in acute infections





#### Questions & Discussion @gallodemoraesMD gallodemoraes.alice@mayo.edu

@gallodemoraesMD

©2016 MFMER | slide-9